Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients
NCT ID: NCT05503030
Last Updated: 2025-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
88 participants
OBSERVATIONAL
2022-12-21
2025-09-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
NCT04702893
A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
NCT05895409
Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
NCT05022784
Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
NCT05875532
Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients
NCT02058602
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nintedanib for CTD-associated PF-ILD patients in Greece
Connective Tissue Disease (CTD)-associated Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Nintedanib
Nintedanib
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nintedanib
Nintedanib
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have been prescribed nintedanib according to the local Summary of Product Characteristics (SmPC) and clinical judgment. Therapy with nintedanib must have been started for clinical reasons independently from the intended patient enrolment into the study at a maximum of 15 days before enrolment into the trial.
Exclusion Criteria
* Patients at baseline with a known condition or reason that will result in withdrawal from the study before the 24-month time point
* Pregnancy or lactation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Private physician
Athens, , Greece
Private physician
Athens, , Greece
"G. Gennimatas" General Hospital of Athens
Athens, , Greece
"Ippokration" General Hospital of Athens
Athens, , Greece
"Laiko" General Hospital of Athens
Athens, , Greece
Private physician
Athens, , Greece
"ATTIKON" University General Hospital
Athens, , Greece
"KAT" General Hospital
Athens, , Greece
University General Hospital of Heraklion
Heraklion, , Greece
University General Hospital of Heraklion
Heraklion, , Greece
Private physician
Ioannina, , Greece
University General Hospital of Ioannina
Ioannina, , Greece
Private physician
Larissa, , Greece
University General Hospital of Larisa
Larissa, , Greece
Private physician
Nea Smirni, Athens, , Greece
Private physician
Pátrai, , Greece
University General Hospital of Patra
Pátrai, , Greece
Private physician
Thessaloniki, , Greece
"Hippokration" General Hospital of Thessaloniki
Thessaloniki, , Greece
"G. Papanikolaou" General University of Thessaloniki
Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1199-0501
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.